Document is current
Any future updates will be listed below
-
Authors
Liu, Wei
Shi, Tao https://orcid.org/0000-0002-9825-3983
Lu, Chun
Che, Keying
Zhang, Zijian
Luo, Yuting
Hirschhorn, Daniel
Wang, Hanbing
Liu, Shaorui
Wang, Yan
Liu, Shuang
Sun, Haiqiao https://orcid.org/0009-0005-2573-9842
Lu, Jun
Liu, Yuan
Shi, Dongquan
Ding, Shuai
Xu, Heping
Lu, Liaoxun
Xu, Jianming
Xin, Jun
Liang, Yinming https://orcid.org/0000-0001-9174-4037
Merghoub, Taha https://orcid.org/0000-0002-1518-5111
Wei, Jia
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (32070942, 32122035, 32000669)
- License Information
-
More Information
Article History
Received: 20 November 2024
Accepted: 22 June 2025
First Online: 15 July 2025
Competing interests
: Y. Li is currently consulting for GemPharmatech Co. J.W. has received research funding from Leap Therapeutics. T.M. is a consultant for Immunos Therapeutics, Daiichi Sankyo Co, TigaTx, Normunity and Pfizer. T.M. is a cofounder and equity holder of IMVAQ Therapeutics. T.M. has received research funding from Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals, Peregrine Pharmaceuticals, Adaptive Biotechnologies, Leap Therapeutics, and Aprea Therapeutics, and currently receives research funding from Bristol-Myers Squibb, Enterome SA, and Realta Life Sciences. T.M. is an inventor on patent applications related to work on oncolytic viral therapy, alpha virus-based vaccine, neo-antigen modeling, CD40, GITR, OX40, PD-1, and CTLA-4. The rest of authors declare no competing interests.
